JP2008541015A - ナノ粒子コンジュゲート - Google Patents
ナノ粒子コンジュゲート Download PDFInfo
- Publication number
- JP2008541015A JP2008541015A JP2008509210A JP2008509210A JP2008541015A JP 2008541015 A JP2008541015 A JP 2008541015A JP 2008509210 A JP2008509210 A JP 2008509210A JP 2008509210 A JP2008509210 A JP 2008509210A JP 2008541015 A JP2008541015 A JP 2008541015A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- specific binding
- binding moiety
- conjugate
- nanoparticle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
- A61K49/0067—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle quantum dots, fluorescent nanocrystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
- C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/588—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with semiconductor nanocrystal label, e.g. quantum dots
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Physics & Mathematics (AREA)
- Materials Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Composite Materials (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Ceramic Engineering (AREA)
- Mathematical Physics (AREA)
- Theoretical Computer Science (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67575905P | 2005-04-28 | 2005-04-28 | |
| US69364705P | 2005-06-24 | 2005-06-24 | |
| PCT/US2006/016444 WO2006116742A2 (en) | 2005-04-28 | 2006-04-28 | Fluorescent nanoparticles conjugated to antibodies via a peg linker |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008541015A true JP2008541015A (ja) | 2008-11-20 |
| JP2008541015A5 JP2008541015A5 (cg-RX-API-DMAC7.html) | 2009-06-18 |
Family
ID=37027499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008509210A Withdrawn JP2008541015A (ja) | 2005-04-28 | 2006-04-28 | ナノ粒子コンジュゲート |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20060246524A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1893241A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2008541015A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006239154A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2606018A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006116742A2 (cg-RX-API-DMAC7.html) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012029342A1 (ja) * | 2010-08-30 | 2012-03-08 | コニカミノルタエムジー株式会社 | 組織染色方法、組織評価方法および生体物質検出方法 |
| JP2014507949A (ja) * | 2011-02-28 | 2014-04-03 | ヴェンタナ メディカル システムズ, インク. | 核染色のための量子ドットの適用 |
| WO2016072341A1 (ja) * | 2014-11-06 | 2016-05-12 | コニカミノルタ株式会社 | 免疫染色法、およびこれに用いられる免疫染色試薬キット |
| WO2016129444A1 (ja) * | 2015-02-12 | 2016-08-18 | コニカミノルタ株式会社 | 抗体結合蛍光体集積ナノ粒子、抗体結合蛍光体集積ナノ粒子の製造方法および免疫染色キット |
| WO2016163345A1 (ja) * | 2015-04-07 | 2016-10-13 | コニカミノルタ株式会社 | 核酸プローブ |
| JPWO2017056844A1 (ja) * | 2015-09-28 | 2018-07-12 | コニカミノルタ株式会社 | 前立腺癌の病理組織診断結果(グリーソンスコア)の推定方法 |
| JP2018523111A (ja) * | 2015-06-30 | 2018-08-16 | アイメック・ヴェーゼットウェーImec Vzw | 分析物認識分子の表面固定 |
| JP2019529341A (ja) * | 2016-07-05 | 2019-10-17 | ナノコ テクノロジーズ リミテッド | リガンドコンジュゲート量子ドットナノ粒子及びこれを用いてdnaメチル化を検出する方法 |
Families Citing this family (149)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060246523A1 (en) | 2005-04-28 | 2006-11-02 | Christopher Bieniarz | Antibody conjugates |
| CN104090095B (zh) * | 2005-11-23 | 2016-06-01 | 文塔纳医疗系统公司 | 分子缀合物 |
| DE102006011507A1 (de) | 2006-03-14 | 2007-09-20 | Lts Lohmann Therapie-Systeme Ag | Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine |
| ATE509033T1 (de) | 2006-03-20 | 2011-05-15 | Univ California | Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting |
| WO2007122259A1 (en) * | 2006-04-25 | 2007-11-01 | Centre National De La Recherche Scientifique (Cnrs) | Functionalization of gold nanoparticles with oriented proteins. application to the high-density labelling of cell membranes |
| EP3276349B1 (en) | 2006-11-01 | 2019-08-07 | Ventana Medical Systems, Inc. | Haptens, hapten conjugates, compositions thereof and method for their preparation and use |
| FR2909881A1 (fr) * | 2006-12-14 | 2008-06-20 | Inst Nat Sante Rech Med | Nouveaux conjugues, utilisables a des fins therapeutiques, et/ou a titre d'agent de diagnostic et/ou d'imagerie et leur procede de preparation |
| WO2008147481A1 (en) * | 2007-02-09 | 2008-12-04 | Northeastern University | Precision-guided nanoparticle systems for drug delivery |
| US7682789B2 (en) * | 2007-05-04 | 2010-03-23 | Ventana Medical Systems, Inc. | Method for quantifying biomolecules conjugated to a nanoparticle |
| US7985557B2 (en) | 2007-05-23 | 2011-07-26 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
| WO2009025364A1 (ja) * | 2007-08-23 | 2009-02-26 | Mitsubishi Kagaku Iatron, Inc. | 非特異反応抑制剤 |
| US8940298B2 (en) | 2007-09-04 | 2015-01-27 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection |
| US8551072B2 (en) * | 2007-12-12 | 2013-10-08 | Boston Scientific Scimed, Inc. | Methods, devices and compositions for controlled drug delivery to injured myocardium |
| US20090181183A1 (en) * | 2008-01-14 | 2009-07-16 | Xerox Corporation | Stabilized Metal Nanoparticles and Methods for Depositing Conductive Features Using Stabilized Metal Nanoparticles |
| US20090270269A1 (en) * | 2008-04-28 | 2009-10-29 | Ashok Kumar | Nano-scale fluoro-biosensors exhibiting a low false alarm rate for rapid detection of biological contaminants |
| KR101153748B1 (ko) * | 2008-05-07 | 2012-06-14 | 재단법인서울대학교산학협력재단 | 바이오센서로 유용한 새로운 형태의 금/은 코어쉘 복합체 |
| CA2979353C (en) | 2008-06-05 | 2020-06-30 | Ventana Medical Systems, Inc. | Compositions comprising nanomaterials and method for using such compositions for histochemical processes |
| US20100069616A1 (en) * | 2008-08-06 | 2010-03-18 | The Regents Of The University Of California | Engineered antibody-nanoparticle conjugates |
| ES2915692T3 (es) | 2008-08-13 | 2022-06-24 | California Inst Of Techn | Nanopartículas portadoras y composiciones, métodos y sistemas relacionados |
| US20100136584A1 (en) * | 2008-09-22 | 2010-06-03 | Icb International, Inc. | Methods for using antibodies and analogs thereof |
| WO2010043053A1 (en) * | 2008-10-15 | 2010-04-22 | National Research Council Of Canada | Single-domain antibody functionalized quantum dots for cellular imaging of cancer cells |
| JP5838169B2 (ja) | 2009-12-31 | 2016-01-06 | ヴェンタナ メディカル システムズ, インク. | 一意的に特異的核酸プローブを生成するための方法 |
| USPP22463P3 (en) * | 2010-02-16 | 2012-01-17 | Menachem Bornstein | Gypsophila plant named ‘Pearl Blossom’ |
| AU2011220792A1 (en) | 2010-02-26 | 2012-07-26 | Ventana Medical Systems, Inc. | Cytogenic analysis of metaphase chromosomes |
| DK2539355T3 (da) | 2010-02-26 | 2017-01-02 | Ventana Med Syst Inc | IN-SITU-hybridisering med polytag-prober |
| CA2796087A1 (en) | 2010-04-20 | 2011-10-27 | Ventana Medical Systems, Inc. | Two-color chromogenic in situ hybridization |
| CA2792569C (en) | 2010-04-27 | 2019-01-15 | Ventana Medical Systems, Inc. | Antibody-nanoparticle conjugates and methods for making and using such conjugates |
| DK2588144T3 (en) | 2010-07-02 | 2018-07-23 | Ventana Med Syst Inc | Detection of targets using mass markers and mass spectrometry |
| US20130109019A1 (en) | 2010-07-02 | 2013-05-02 | Adrian E. Murillo | Hapten conjugates for target detection |
| US9127028B2 (en) | 2010-08-16 | 2015-09-08 | Ventana Medical Systems, Inc. | Substrates for chromogenic detection and methods of use in detection assays and kits |
| CA2851101C (en) | 2010-10-06 | 2017-02-14 | Biocare Medical, Llc | Methods and systems for efficient processing of biological samples |
| CN103649713B (zh) | 2010-11-29 | 2017-03-01 | 丹麦达科有限公司 | 由可编程性定量检定所处理的样本的图像分析方法和体系 |
| US20120148488A1 (en) * | 2010-12-10 | 2012-06-14 | California Institute Of Technology | Targeting Kidney Mesangium With Nanoparticles of Defined Diameter |
| KR101779610B1 (ko) * | 2011-01-17 | 2017-09-18 | 엘지전자 주식회사 | 면역 센서에서 검출 신호를 증폭하기 위한 키트 및 이를 이용한 표적 항원의 검출 방법 |
| WO2012109538A2 (en) | 2011-02-10 | 2012-08-16 | President And Fellows Of Harvard College | Surrogates of post-translationally modified proteins and uses thereof |
| US9945763B1 (en) | 2011-02-18 | 2018-04-17 | Biocare Medical, Llc | Methods and systems for immunohistochemistry heat retrieval of biological samples |
| US9562259B2 (en) | 2011-03-14 | 2017-02-07 | Ventana Medical Systems, Inc. | Method of analyzing chromosomal inversions |
| KR20120128440A (ko) * | 2011-05-17 | 2012-11-27 | 삼성전자주식회사 | 표적 물질 검출용 키트 및 이를 이용한 표적 물질 검출 방법 |
| US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
| WO2013167387A1 (en) | 2012-05-10 | 2013-11-14 | Ventana Medical Systems, Inc. | Uniquely specific probes for pten, pik3ca, met, top2a, and mdm2 |
| JP6923291B2 (ja) | 2012-07-12 | 2021-08-18 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 少なくとも7個の遺伝子のサインを用いて、固形癌を患う患者の生存期間および処置に対する応答性を予測するための方法 |
| LT2880180T (lt) | 2012-08-06 | 2019-01-25 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Būdai ir rinkiniai, skirti vėžiu sergančių pacientų atrankai |
| WO2014048942A1 (en) | 2012-09-25 | 2014-04-03 | Ventana Medical Systems, Inc. | Probes for pten, pik3ca, met, and top2a, and method for using the probes |
| US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
| WO2014139979A1 (en) * | 2013-03-12 | 2014-09-18 | Ventana Medical Systems, Inc. | Quantum dot in situ hybridization |
| DK2971064T3 (da) | 2013-03-12 | 2019-12-16 | Ventana Med Syst Inc | Nærhedsassay til in situ-påvisning af mål |
| CN103293293B (zh) * | 2013-06-24 | 2015-01-14 | 浙江大学 | 用于无标记癌胚抗原检测的电化学免疫传感器的制备方法 |
| WO2015001082A1 (en) | 2013-07-05 | 2015-01-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof |
| WO2015026663A1 (en) | 2013-08-19 | 2015-02-26 | University Of Houston | Phosphorescent reporters |
| WO2015036405A1 (en) | 2013-09-10 | 2015-03-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating basal cell carcinoma |
| AU2015255883A1 (en) * | 2014-05-08 | 2016-10-27 | Novodiax, Inc. | Direct immunohistochemistry assay |
| EP3001833B1 (en) * | 2014-06-25 | 2019-01-23 | Bio-Rad Laboratories, Inc. | Purification of nanoparticle-antibody conjugates |
| EP3009147A1 (en) | 2014-10-16 | 2016-04-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for treating resistant glioblastoma |
| CN107003323B (zh) | 2014-11-25 | 2019-06-04 | 文塔纳医疗系统公司 | 使用化学连接和半抗原转移的邻近测定法 |
| EP3317323B1 (en) | 2015-07-01 | 2021-05-26 | California Institute of Technology | Cationic mucic acid polymer-based delivery systems |
| CN106338423B (zh) | 2015-07-10 | 2020-07-14 | 三斯坎公司 | 组织学染色的空间复用 |
| WO2017029391A1 (en) | 2015-08-20 | 2017-02-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method for treating cancer |
| WO2017055324A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of cells of monocytic origin in a tissue sample |
| WO2017055319A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of b cells in a tissue sample |
| WO2017055320A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample |
| WO2017055325A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of nk cells in a tissue sample |
| WO2017055327A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of endothelial cells in a tissue sample |
| WO2017055321A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of fibroblasts in a tissue sample |
| WO2017055322A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of neutrophils in a tissue sample |
| WO2017055326A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of myeloid dendritic cells in a tissue sample |
| WO2017060397A1 (en) | 2015-10-09 | 2017-04-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of subjects suffering from melanoma metastases |
| WO2017067944A1 (en) | 2015-10-19 | 2017-04-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of subjects suffering from triple negative breast cancer |
| WO2017083659A1 (en) * | 2015-11-12 | 2017-05-18 | New York University | Biodegradable polymeric nanoparticle conjugates and use thereof |
| WO2017117275A1 (en) * | 2015-12-31 | 2017-07-06 | City Of Hope | Silica nanoparticle with platinum anti-cancer agent |
| WO2017182834A1 (en) | 2016-04-19 | 2017-10-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method for treating resistant glioblastoma |
| WO2017202962A1 (en) | 2016-05-24 | 2017-11-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd) |
| CN109715196A (zh) | 2016-06-13 | 2019-05-03 | 转矩医疗股份有限公司 | 用于促进免疫细胞功能的组合物和方法 |
| WO2018011107A1 (en) | 2016-07-11 | 2018-01-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of er-alpha 46 in methods and kits for assessing the status of breast cancer |
| WO2018011166A2 (en) | 2016-07-12 | 2018-01-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of myeloid dendritic cells in a tissue sample |
| WO2018046736A1 (en) | 2016-09-12 | 2018-03-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of patients suffering from cancer |
| EP3295933A1 (en) * | 2016-09-14 | 2018-03-21 | Ecole Polytechnique Federale De Lausanne (Epfl) | Hydrogels based on functionalized polysaccharides |
| US11542371B2 (en) | 2016-09-14 | 2023-01-03 | Ecole Polytechnique Federale De Lausanne (Epfl) | Hydrogels based on functionalized polysaccharides |
| EP3516071B1 (en) | 2016-09-22 | 2021-02-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of lung cancer |
| EP3515453A1 (en) | 2016-09-22 | 2019-07-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof |
| US10814305B2 (en) * | 2016-09-29 | 2020-10-27 | Bio-Rad Laboratories, Inc. | Agarose-filled ceramic apatite |
| WO2018118759A1 (en) | 2016-12-19 | 2018-06-28 | Ventana Medical Systems, Inc. | Peptide nucleic acid conjugates |
| WO2018122249A1 (en) | 2016-12-28 | 2018-07-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer |
| WO2018122245A1 (en) | 2016-12-28 | 2018-07-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting the survival time of patients suffering from cms3 colorectal cancer |
| WO2018146239A1 (en) | 2017-02-10 | 2018-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Biomarker for outcome in aml patients |
| WO2018162404A1 (en) | 2017-03-06 | 2018-09-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Biomarker for outcome in aml patients |
| WO2018172540A1 (en) | 2017-03-24 | 2018-09-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to predict the progression of alzheimer's disease |
| WO2018189215A1 (en) | 2017-04-12 | 2018-10-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for predicting the survival time of a patient suffering from hepatocellular carcinoma |
| WO2018195008A1 (en) | 2017-04-21 | 2018-10-25 | Mellitus, Llc | Methods and antibodies for diabetes-related applications |
| CN107389913B (zh) * | 2017-06-26 | 2019-05-17 | 清华大学 | 生物传感器及生物检测方法 |
| WO2019038219A1 (en) | 2017-08-21 | 2019-02-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New prognostic method of pancreatic cancer |
| WO2019043138A1 (en) | 2017-09-01 | 2019-03-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | METHOD FOR PREDICTING OUTCOME OF CANCER |
| CA3074826A1 (en) | 2017-09-05 | 2019-03-14 | Torque Therapeutics, Inc. | Therapeutic protein compositions and methods of making and using the same |
| WO2019092269A1 (en) | 2017-11-13 | 2019-05-16 | F. Hoffmann-La Roche Ag | Devices for sample analysis using epitachophoresis |
| EP3716949A4 (en) * | 2017-11-29 | 2022-05-18 | UTI Limited Partnership | METHODS OF TREATMENT OF AUTOIMMUNE DISEASES |
| JP7727385B2 (ja) | 2017-12-18 | 2025-08-21 | ヴェンタナ メディカル システムズ, インク. | ペプチド核酸コンジュゲート |
| EP3755381B1 (en) | 2018-02-21 | 2025-01-01 | Sorbonne Université | Optical imaging agents targeting inflammation |
| WO2019207030A1 (en) | 2018-04-26 | 2019-10-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer |
| US20190381188A1 (en) | 2018-06-13 | 2019-12-19 | California Institute Of Technology | Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same |
| EP3864403A1 (en) | 2018-10-12 | 2021-08-18 | F. Hoffmann-La Roche AG | Detection methods for epitachophoresis workflow automation |
| WO2020089428A1 (en) | 2018-11-02 | 2020-05-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New prognostic method of pancreatic cancer |
| WO2020089432A1 (en) | 2018-11-02 | 2020-05-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New prognostic method of pancreatic cancer |
| MX2021008121A (es) | 2019-01-03 | 2021-12-10 | Inst Nat Sante Rech Med | Metodos y composiciones farmaceuticas para mejorar las respuestas inmunitarias dependientes de celulas t cd8+ en sujetos que sufren de cancer. |
| EP3911669A1 (en) | 2019-01-16 | 2021-11-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Variants of erythroferrone and their use |
| EP3924520A1 (en) | 2019-02-13 | 2021-12-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for selecting a cancer treatment in a subject suffering from cancer |
| WO2020182932A1 (en) | 2019-03-13 | 2020-09-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New gene signatures for predicting survival time in patients suffering from renal cell carcinoma |
| WO2020193740A1 (en) | 2019-03-28 | 2020-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New strategy for treating pancreatic cancer |
| WO2020201362A2 (en) | 2019-04-02 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
| WO2020216832A1 (en) | 2019-04-24 | 2020-10-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for predicting the response of antipsychotic drugs |
| WO2020229521A1 (en) | 2019-05-14 | 2020-11-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for inhibiting or reducing bacterial biofilms on a surface |
| JP7441243B2 (ja) | 2019-05-14 | 2024-02-29 | エフ. ホフマン-ラ ロシュ アーゲー | 試料分析のための装置および方法 |
| CN114072676B (zh) | 2019-06-03 | 2024-07-12 | 法国国家卫生及研究医学协会 | 调节治疗方案的方法 |
| WO2021001539A1 (en) | 2019-07-04 | 2021-01-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New strategy to detect and treat eosinophilic fasciitis |
| US20220340975A1 (en) | 2019-09-05 | 2022-10-27 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Method of treatment and pronostic of acute myeloid leukemia |
| EP4045686A1 (en) | 2019-10-17 | 2022-08-24 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for diagnosing nasal intestinal type adenocarcinomas |
| JP7577538B2 (ja) | 2020-02-19 | 2024-11-05 | バイオ-ラッド ラボラトリーズ インコーポレーティッド | ポリマー充填クロマトグラフィー樹脂を調製する方法 |
| WO2021170777A1 (en) | 2020-02-28 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing, prognosing and managing treatment of breast cancer |
| EP4121768A1 (en) | 2020-03-20 | 2023-01-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for predicting the survival time of a patient suffering from a cancer |
| JP2023528978A (ja) | 2020-06-10 | 2023-07-06 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 悪性膠芽腫のような癌の治療及び予防方法 |
| WO2021255204A1 (en) | 2020-06-18 | 2021-12-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New strategy for treating pancreatic cancer |
| EP4172621A1 (en) | 2020-06-30 | 2023-05-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies |
| JP7741831B2 (ja) | 2020-06-30 | 2025-09-18 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 術前補助療法及び根治手術後の固形がんを患っている患者の再発及び/又は死亡のリスクを予測するための方法 |
| WO2022018163A1 (en) | 2020-07-22 | 2022-01-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for predicting survival time in patients suffering from cancer |
| WO2022064049A1 (en) | 2020-09-28 | 2022-03-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for diagnosing brucella infection |
| EP4232603A1 (en) | 2020-10-20 | 2023-08-30 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Method for predicting the response to tnf inhibitors |
| JP2023548421A (ja) | 2020-11-06 | 2023-11-16 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | 多のう胞性卵巣症候群(pcos)を診断および処置するための方法 |
| WO2022136252A1 (en) | 2020-12-21 | 2022-06-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for prognosis the humoral response of a subject prior to vaccination |
| WO2022135753A1 (en) | 2020-12-21 | 2022-06-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for prognosis the humoral response of a subject prior to vaccination |
| WO2022152698A1 (en) | 2021-01-12 | 2022-07-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of npdk-d to evaluate cancer prognosis |
| EP4291897A1 (en) | 2021-02-09 | 2023-12-20 | Institut National de la Santé et de la Recherche Médicale (INSERM) | New method to pronostic lung cancer |
| US20240159760A1 (en) | 2021-03-17 | 2024-05-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for diagnosing pancreatic cancer |
| WO2022207566A1 (en) | 2021-03-29 | 2022-10-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method to evaluate pancreatic cancer prognosis |
| EP4326903A1 (en) | 2021-04-23 | 2024-02-28 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating cell senescence accumulation related disease |
| US20240316005A1 (en) | 2021-07-05 | 2024-09-26 | Institut National de la Santé et de la Recherche Médicale | Gene signatures for predicting survival time in patients suffering from renal cell carcinoma |
| WO2023089159A1 (en) | 2021-11-22 | 2023-05-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New strategy targeting stroma/tumor cell crosstalk to treat a cancer |
| WO2023144303A1 (en) | 2022-01-31 | 2023-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cd38 as a biomarker and biotarget in t-cell lymphomas |
| WO2023152133A1 (en) | 2022-02-08 | 2023-08-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for diagnosing colorectal cancer |
| US20250035635A1 (en) | 2022-03-17 | 2025-01-30 | Institut National De La Sante Et De La Recherche Medicale | Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer |
| WO2024061930A1 (en) | 2022-09-22 | 2024-03-28 | Institut National de la Santé et de la Recherche Médicale | New method to treat and diagnose peripheral t-cell lymphoma (ptcl) |
| WO2024115935A1 (en) | 2022-11-29 | 2024-06-06 | Inserm | Methods for the treatment of b-cell lymphoma using cd39 inhibitors |
| WO2024236131A1 (en) | 2023-05-17 | 2024-11-21 | Institut National de la Santé et de la Recherche Médicale | Stratificate and method to treat a patient suffering from a cancer |
| WO2024245951A1 (en) | 2023-05-26 | 2024-12-05 | Institut National de la Santé et de la Recherche Médicale | Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma |
| WO2025027127A1 (en) | 2023-08-02 | 2025-02-06 | Institut National de la Santé et de la Recherche Médicale | New prognostic method of kidney failure |
| WO2025068340A1 (en) | 2023-09-27 | 2025-04-03 | Institut National de la Santé et de la Recherche Médicale | Method to predict aml outcome |
| EP4788839A1 (en) | 2023-10-03 | 2026-08-12 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
| WO2025078632A1 (en) | 2023-10-12 | 2025-04-17 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from cancer |
| WO2025109147A1 (en) | 2023-11-24 | 2025-05-30 | Institut National de la Santé et de la Recherche Médicale | Method to predict the risk of a cardiovascular event in a patient with type 2 diabetes |
| WO2025114473A1 (en) | 2023-11-29 | 2025-06-05 | Institut National de la Santé et de la Recherche Médicale | Method for assessing diseases associated with a loss of p53 function in subjects in need thereof |
| WO2026013153A1 (en) | 2024-07-10 | 2026-01-15 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from myc-high tumors |
| WO2026093526A1 (en) | 2024-10-31 | 2026-05-07 | Institut National de la Santé et de la Recherche Médicale | Methods of predicting cancer in patients having premalignant lesions |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3654090A (en) * | 1968-09-24 | 1972-04-04 | Organon | Method for the determination of antigens and antibodies |
| NL154599B (nl) * | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US4002532A (en) * | 1974-10-21 | 1977-01-11 | Weltman Joel K | Enzyme conjugates |
| IL47468A (en) * | 1975-06-12 | 1979-05-31 | Rehovot Res Prod | Process for the cross-linking of proteins using water soluble cross-linking agents |
| US4016043A (en) * | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| JPS5344622A (en) * | 1976-09-30 | 1978-04-21 | Mochida Pharm Co Ltd | Immunologically measuring method |
| DE2708018A1 (de) * | 1977-02-24 | 1978-09-07 | Boehringer Mannheim Gmbh | An polyamid fixiertes biologisch aktives protein und verfahren zu seiner herstellung |
| SE427505B (sv) * | 1977-03-04 | 1983-04-11 | Pharmacia Diagnostics Ab | Reagens till anvendning vid immunkemiska bestemningsmetoder |
| US4235960A (en) * | 1977-07-29 | 1980-11-25 | The Medical College Of Wisconsin, Inc. | Competitive enzyme-linked immunoassay |
| US4218539A (en) * | 1978-03-24 | 1980-08-19 | Weltman Joel K | Enzyme conjugates and method of preparation and use |
| US4232960A (en) * | 1979-02-21 | 1980-11-11 | Xerox Corporation | Scanning system |
| US4433059A (en) * | 1981-09-08 | 1984-02-21 | Ortho Diagnostic Systems Inc. | Double antibody conjugate |
| US4671958A (en) * | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4454226A (en) * | 1982-03-17 | 1984-06-12 | Majid Ali | Enzymatic immunoassay |
| US4657853A (en) * | 1984-09-14 | 1987-04-14 | E. I. Du Pont De Nemours And Company | Immunoassays utilizing covalent conjugates of polymerized enzyme and antibody |
| US4732863A (en) * | 1984-12-31 | 1988-03-22 | University Of New Mexico | PEG-modified antibody with reduced affinity for cell surface Fc receptors |
| US4657958A (en) * | 1985-03-05 | 1987-04-14 | The Firestone Tire & Rubber Company | Contact adhesive and adhesive system for EPDM elastomers |
| US5057313A (en) * | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| US4810638A (en) * | 1986-07-24 | 1989-03-07 | Miles Inc. | Enzyme-labeled antibody reagent with polyalkyleneglycol linking group |
| US5002883A (en) * | 1987-10-30 | 1991-03-26 | Abbott Laboratories | Covalent attachment of antibodies and antigens to solid phases using extended length heterobifunctional coupling agents |
| US4994385A (en) * | 1987-10-30 | 1991-02-19 | Abbott Laboratories | Heterobifunctional coupling agents |
| US5053520A (en) * | 1988-09-22 | 1991-10-01 | Abbott Laboratories | Heterobifunctional maleimido containing coupling agents |
| US5063109A (en) * | 1988-10-11 | 1991-11-05 | Abbott Laboratories | Covalent attachment of antibodies and antigens to solid phases using extended length heterobifunctional coupling agents |
| US5191066A (en) * | 1990-12-07 | 1993-03-02 | Abbott Laboratories | Site-specific conjugation of immunoglobulins and detectable labels |
| US5329028A (en) * | 1992-08-05 | 1994-07-12 | Genentech, Inc. | Carbohydrate-directed cross-linking reagents |
| DE69334275D1 (de) * | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| US6005079A (en) * | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| US5648218A (en) * | 1993-02-12 | 1997-07-15 | Sealite Sciences, Inc. | Preparation of photoprotein conjugates and methods of use thereof |
| US5736624A (en) * | 1994-12-02 | 1998-04-07 | Abbott Laboratories | Phosphatase activated crosslinking, conjugating and reducing agents; methods of using such agents; and reagents comprising phosphatase activated crosslinking and conjugating agents |
| DE59607898D1 (de) * | 1995-12-29 | 2001-11-15 | Biotez Berlin Buch Gmbh Bioche | Verfahren zur markierung von biomolekülen mit meerrettichperoxidase |
| US6218160B1 (en) * | 1997-10-31 | 2001-04-17 | Roche Diagnostics Corporation | Site-specific conjugation of glycoproteins |
| JP3524401B2 (ja) * | 1998-09-16 | 2004-05-10 | 株式会社ニチレイ | 酵素抗体複合体およびその製造方法 |
| ATE234468T1 (de) * | 1998-09-18 | 2003-03-15 | Massachusetts Inst Technology | Biologische verwendungen von halbleitenden nanokristallen |
| US6576746B2 (en) * | 1998-10-13 | 2003-06-10 | Immunomedics, Inc. | Site-specific labeling of disulfide-containing targeting vectors |
| WO2000068692A1 (en) * | 1999-05-07 | 2000-11-16 | Quantum Dot Corporation | A method of detecting an analyte using semiconductor nanocrystals |
| JP3781934B2 (ja) * | 1999-12-22 | 2006-06-07 | 株式会社ニチレイバイオサイエンス | 酵素−タンパク質複合体 |
| EP1118334A1 (en) * | 2000-01-11 | 2001-07-25 | Aventis Behring Gesellschaft mit beschränkter Haftung | Method for the production of conjugates and uses thereof for the prevention and treatment of allergic reactions and autoimmune diseases |
| EP1118335A1 (en) * | 2000-01-11 | 2001-07-25 | Aventis Behring GmbH | Method for the production of conjugates for the treatment of allergic reactions and autoimmune diseases |
| AU2001247697B2 (en) * | 2000-03-22 | 2006-06-22 | Solulink, Incorporated | Hydrazine-based and carbonyl-based bifunctional crosslinking reagents |
| US6649138B2 (en) * | 2000-10-13 | 2003-11-18 | Quantum Dot Corporation | Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media |
| US20020083888A1 (en) * | 2000-12-28 | 2002-07-04 | Zehnder Donald A. | Flow synthesis of quantum dot nanocrystals |
| EP2218762A3 (en) * | 2001-07-20 | 2010-09-29 | Life Technologies Corporation | Luminescent nanoparticles and methods for their preparation |
| JP2003322654A (ja) * | 2002-02-27 | 2003-11-14 | Hitachi Software Eng Co Ltd | 生体高分子の検出方法 |
| EP1539811A4 (en) * | 2002-09-16 | 2006-05-24 | Elusys Therapeutics Inc | PREPARATION OF BISPEQIFIC MOLECULES WITH POLYETHYLENE GLYCOL LINKER |
| US7217845B2 (en) * | 2002-11-25 | 2007-05-15 | Sun Bio, Inc. | Bifunctional polyethylene glycol derivatives |
| US7888536B2 (en) * | 2004-02-13 | 2011-02-15 | Quanta Biodesign, Ltd. | Selective and specific preparation of discrete PEG compounds |
| JP4181435B2 (ja) * | 2003-03-31 | 2008-11-12 | 日油株式会社 | ポリエチレングリコール修飾半導体微粒子、その製造法及び生物学的診断用材料 |
| KR100657891B1 (ko) * | 2003-07-19 | 2006-12-14 | 삼성전자주식회사 | 반도체 나노결정 및 그 제조방법 |
| US7541455B2 (en) * | 2003-12-22 | 2009-06-02 | Ventana Medical Systems, Inc. | Microwave mediated synthesis of nucleic acid probes |
| US20050186642A1 (en) * | 2004-02-24 | 2005-08-25 | Biocare Medical, Inc. | Immunoassay reagents and methods of use thereof |
| US7361516B2 (en) * | 2004-09-24 | 2008-04-22 | The United States Of America As Represented By The Secretary Of The Navy | Field of modular multifunctional ligands |
| US20060246523A1 (en) * | 2005-04-28 | 2006-11-02 | Christopher Bieniarz | Antibody conjugates |
| WO2007048127A2 (en) * | 2005-10-20 | 2007-04-26 | The Scripps Research Institute | Fc labeling for immunostaining and immunotargeting |
| CN104090095B (zh) * | 2005-11-23 | 2016-06-01 | 文塔纳医疗系统公司 | 分子缀合物 |
-
2006
- 2006-04-28 EP EP06758784A patent/EP1893241A2/en not_active Withdrawn
- 2006-04-28 CA CA002606018A patent/CA2606018A1/en not_active Abandoned
- 2006-04-28 AU AU2006239154A patent/AU2006239154A1/en not_active Abandoned
- 2006-04-28 WO PCT/US2006/016444 patent/WO2006116742A2/en not_active Ceased
- 2006-04-28 JP JP2008509210A patent/JP2008541015A/ja not_active Withdrawn
- 2006-04-28 US US11/413,778 patent/US20060246524A1/en not_active Abandoned
-
2009
- 2009-03-16 US US12/381,729 patent/US20090181398A1/en not_active Abandoned
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012029342A1 (ja) * | 2010-08-30 | 2012-03-08 | コニカミノルタエムジー株式会社 | 組織染色方法、組織評価方法および生体物質検出方法 |
| JPWO2012029342A1 (ja) * | 2010-08-30 | 2013-10-28 | コニカミノルタ株式会社 | 組織染色方法、組織評価方法および生体物質検出方法 |
| JP2015111167A (ja) * | 2010-08-30 | 2015-06-18 | コニカミノルタ株式会社 | 組織染色方法および生体物質検出方法 |
| US10809167B2 (en) | 2010-08-30 | 2020-10-20 | Konica Minolta, Inc. | Tissue staining method with staining agent containing particle holding plural phosphors |
| US10627325B2 (en) | 2010-08-30 | 2020-04-21 | Konica Minolta, Inc. | Fluorescent marker for tissue staining containing phosphor-containing nanoparticle and method using same |
| JP2014507949A (ja) * | 2011-02-28 | 2014-04-03 | ヴェンタナ メディカル システムズ, インク. | 核染色のための量子ドットの適用 |
| WO2016072341A1 (ja) * | 2014-11-06 | 2016-05-12 | コニカミノルタ株式会社 | 免疫染色法、およびこれに用いられる免疫染色試薬キット |
| JPWO2016072341A1 (ja) * | 2014-11-06 | 2017-08-10 | コニカミノルタ株式会社 | 免疫染色法、およびこれに用いられる免疫染色試薬キット |
| JPWO2016129444A1 (ja) * | 2015-02-12 | 2017-11-24 | コニカミノルタ株式会社 | 抗体結合蛍光体集積ナノ粒子、抗体結合蛍光体集積ナノ粒子の製造方法および免疫染色キット |
| WO2016129444A1 (ja) * | 2015-02-12 | 2016-08-18 | コニカミノルタ株式会社 | 抗体結合蛍光体集積ナノ粒子、抗体結合蛍光体集積ナノ粒子の製造方法および免疫染色キット |
| JPWO2016163345A1 (ja) * | 2015-04-07 | 2018-02-15 | コニカミノルタ株式会社 | 核酸プローブ |
| WO2016163345A1 (ja) * | 2015-04-07 | 2016-10-13 | コニカミノルタ株式会社 | 核酸プローブ |
| JP2018523111A (ja) * | 2015-06-30 | 2018-08-16 | アイメック・ヴェーゼットウェーImec Vzw | 分析物認識分子の表面固定 |
| JP2021144051A (ja) * | 2015-06-30 | 2021-09-24 | アイメック・ヴェーゼットウェーImec Vzw | 分析物認識分子の表面固定 |
| JPWO2017056844A1 (ja) * | 2015-09-28 | 2018-07-12 | コニカミノルタ株式会社 | 前立腺癌の病理組織診断結果(グリーソンスコア)の推定方法 |
| JP2019529341A (ja) * | 2016-07-05 | 2019-10-17 | ナノコ テクノロジーズ リミテッド | リガンドコンジュゲート量子ドットナノ粒子及びこれを用いてdnaメチル化を検出する方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20060246524A1 (en) | 2006-11-02 |
| AU2006239154A1 (en) | 2006-11-02 |
| CA2606018A1 (en) | 2006-11-02 |
| WO2006116742A2 (en) | 2006-11-02 |
| US20090181398A1 (en) | 2009-07-16 |
| EP1893241A2 (en) | 2008-03-05 |
| WO2006116742A3 (en) | 2008-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090181398A1 (en) | Nanoparticle conjugates | |
| Razo et al. | Double-enhanced lateral flow immunoassay for potato virus X based on a combination of magnetic and gold nanoparticles | |
| Mohammadi et al. | A FRET immunosensor for sensitive detection of CA 15-3 tumor marker in human serum sample and breast cancer cells using antibody functionalized luminescent carbon-dots and AuNPs-dendrimer aptamer as donor-acceptor pair | |
| Babamiri et al. | Ultrasensitive electrochemiluminescence immunoassay for simultaneous determination of CA125 and CA15-3 tumor markers based on PAMAM-sulfanilic acid-Ru (bpy) 32+ and PAMAM-CdTe@ CdS nanocomposite | |
| Wang et al. | An ultrasensitive homogeneous aptasensor for carcinoembryonic antigen based on upconversion fluorescence resonance energy transfer | |
| Hamd-Ghadareh et al. | An amplified comparative fluorescence resonance energy transfer immunosensing of CA125 tumor marker and ovarian cancer cells using green and economic carbon dots for bio-applications in labeling, imaging and sensing | |
| Sukhanova et al. | Highly stable fluorescent nanocrystals as a novel class of labels for immunohistochemical analysis of paraffin-embedded tissue sections | |
| Sahoo et al. | Biocompatible quantum dot-antibody conjugate for cell imaging, targeting and fluorometric immunoassay: crosslinking, characterization and applications | |
| Mazumder et al. | Biofunctionalized quantum dots in biology and medicine | |
| JP2021152545A (ja) | S−アデノシルメチオニン、s−アデノシルホモシステイン及びホモシステインを迅速かつ簡単に測定するための蛍光の使用 | |
| Deb et al. | Biogenic carbon dot-based fluorescence-mediated immunosensor for the detection of disease biomarker | |
| Samir et al. | Quantum dots: heralding a brighter future for clinical diagnostics | |
| Pereira et al. | (Bio) conjugation strategies applied to fluorescent semiconductor quantum dots | |
| US20110070662A1 (en) | Raman-active reagents and the use thereof | |
| Kavosi et al. | Amplified fluorescence resonance energy transfer sensing of prostate specific antigen based on aggregation of CdTe QDs/antibody and aptamer decorated of AuNPs-PAMAM dendrimer | |
| Babamiri et al. | Potential-resolved electrochemiluminescence immunoassay for simultaneous determination of CEA and AFP tumor markers using dendritic nanoclusters and Fe3O4@ SiO2 nanoparticles | |
| Sun et al. | Using fluorescence immunochromatographic test strips based on quantum dots for the rapid and sensitive determination of microcystin-LR: J. Sun et al. | |
| Gharaat et al. | A dextran mediated multicolor immunochromatographic rapid test strip for visual and instrumental simultaneous detection of Vibrio cholera O1 (Ogawa) and Clostridium botulinum toxin A | |
| Mukundan et al. | Optimizing a waveguide-based sandwich immunoassay for tumor biomarkers: evaluating fluorescent labels and functional surfaces | |
| Mahdi et al. | Competitive immunoassay for Ochratoxin a based on FRET from quantum dot-labeled antibody to rhodamine-coated magnetic silica nanoparticles | |
| Stanisavljevic et al. | Capillary electrophoresis of quantum dots: Minireview | |
| Bailes et al. | Gold nanoparticle antibody conjugates for use in competitive lateral flow assays | |
| Li et al. | Simultaneous fluoroimmunoassay of two tumor markers based on CdTe quantum dots and gold nanocluster coated-silica nanospheres as labels | |
| Abramova et al. | Luminescence semiconductor quantum dots in chemical analysis | |
| Bahari et al. | An eco-friendly MIP-solid surface fluorescence immunosensor for detection of CA 19-9 tumor marker using Ni nanocluster as an emitter labels |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090423 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090423 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110329 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20110408 |